Access to new drugs for rare disorders in Canada

McMillan and Campbell believe that Canada needs a regulatory framework for the introduction of orphan drugs for rare disorders.[1][1] We agree. However, the need is unlikely to be met in the foreseeable future because, in October 2017, the present federal government deleted from the Health Canada